News Releases

September 19, 2018 at 4:01 PM EDT

Summary Toggle Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock

AUSTIN, Texas , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic
September 19, 2018 at 8:00 AM EDT

Summary Toggle Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy

The Agreement Will Support the Development of a Potential New Treatment Option for Multiple Myeloma AUSTIN, Texas , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM) today announced an agreement with Takeda Pharmaceutical Company Limited (Takeda) for the joint development
August 9, 2018 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Reports Second Quarter 2018 Financial Results

AUSTIN, Texas , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,
June 21, 2018 at 4:30 PM EDT

Summary Toggle Molecular Templates Set to Join the Russell 3000® and Russell Microcap® Indexes

AUSTIN, Texas , June 21, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in
June 4, 2018 at 4:30 PM EDT

Summary Toggle Molecular Templates Presents Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018

ASCO Posters Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas , June 04, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies
May 31, 2018 at 4:05 PM EDT

Summary Toggle Molecular Templates to Present at the Jefferies Global Healthcare Conference

AUSTIN, Texas , May 31, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics
May 16, 2018 at 5:00 PM EDT

Summary Toggle Molecular Templates to Present Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018

ASCO Posters to Feature Data on MT-3724 and Evofosfamide AUSTIN, Texas , May 16, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. , (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic
May 15, 2018 at 4:30 PM EDT

Summary Toggle Molecular Templates to Present at the UBS Global Healthcare Conference

AUSTIN, Texas , May 15, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics
May 14, 2018 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Reports First Quarter 2018 Financial Results

MT-3724 Phase Ib Ongoing; Combination Studies Expected to Start in 2H18 AUSTIN, Texas , May 14, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin
March 28, 2018 at 4:30 PM EDT

Summary Toggle Molecular Templates, Inc. Reports Fourth Quarter 2017 Financial Results

Update on MT-3724 Provided at World ADC Conference ; More Data Expected in 2Q18 Upcoming Presentations at AACR Conference to Feature Data on PD-L1 Antigen Seeding ETB and HER2 ETB AUSTIN, Texas , March 28, 2018 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq:MTEM) (“Molecular”), a

News Releases

News Releases

About Molecular Templates

Recent Posts

Date	Title and Summary
Toggle SummaryMarch 12, 2020	Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results AUSTIN, Texas , March 12, 2020 (GLOBE NEWSWIRE) -- Molecular Templates , Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies
Toggle SummaryFebruary 28, 2020	Molecular Templates to Present at Three March Investor Conferences AUSTIN, Texas , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,